RESPONSE

I. Status of the Claims

Prior to the present Action, claims 1-30 and 34-43 were pending (Third Action at page 2, first paragraph). The Summary page and the Action at page 2 include certain errors, in that the Summary page lists claim 16 as both withdrawn and rejected, and does not account for claim 14, and that the Action at page 2, second paragraph omits claim 43 from the pending claims. According to a species election requirement, claims 2, 13, 15-18, 30 and 36-38 are said to be withdrawn as reading on the non-elected species, although this remains contested (see **Section V** for discussion of species).

Presently, claim 12 has been amended to further improve the clarity of expression. No claims have been canceled. Claims 44-48 have been added, which are fully supported by the application as filed, are unified with the examined claims. The new claims would be properly enterable after final rejection, and are anyway enterable in this case as finality is premature.

Claims 1-30 and 34-48 are therefore in the case. According to the revisions to 37 C.F.R. § 1.121(c), a copy of the pending claims is provided in the amendment section.

II. Finality is Improper

The Third Action is prematurely final and the holding of finality should be withdrawn. As detailed in the enclosed Request to Withdraw Finality of Third Office Action Under MPEP 706.07(d), finality is premature as the Third Action enters a new ground of rejection against several claims, not necessitated by Applicants' amendment or untimely submission of references.

In particular, the Action newly rejects pending and unamended claims 3-12, 14, 19-22 and 39-42, of which claims 39-42 are unamended, independent claims, under 35 U.S.C. § 103(a) over Schroit, Gimbrone and Umeda (see **Section VII**). Finality is therefore premature and the holding of finality should be withdrawn pursuant to MPEP 706.07(d).

12

III. Entry of Amendments

As the Third Action is prematurely final, Applicants are entitled to enter the present amendments as a matter of right.

Even if finality was proper, the present amendments would be entitled to entry after final rejection. The amendments place the application in condition for allowance, or at least, in better form for appeal, and could not have been earlier presented as the position of the Office has only been made clear in the Third Action. The amendments would thus be enterable under 37 C.F.R. §§ 1.116(b) and/or 1.116(c), even if such a showing was necessary.

IV. Support for the Claims

Support for the amended and new claims exists in the pending claims and throughout the original application as filed. Any small entity fees necessary for the introduction of the new claim should be deducted from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002282.

Claim 12 has been revised to even further clarify that where the kits comprise first and second anti-aminophospholipid antibodies, or antigen-binding fragments thereof, the first antibody binds to a first aminophospholipid and the second antibody binds to another aminophospholipid. The revisions clarify the original claim language and also better accord with claim 13. The change is supported by claims 12 and 13, and throughout the specification, e.g., at least at page 7, lines 1-2.

New claim 44 is based upon claim 34 and further defines certain preferred examples of the second anti-cancer agents. The functional definition of the unconjugated antibody, or antigen-binding fragment thereof, as binding to an aminophospholipid on the luminal surface of the vascular endothelial cells of the blood vessels of a vascularized tumor is supported by claims 39-42 and throughout the specification, e.g. at least at page 9, lines 2-3. Preferred second

anti-cancer agents, other than the unconjugated anti-aminophospholipid antibody or antigen-binding fragment thereof, are recited as: (i) an agent that increases aminophospholipid expression, or injures or induces apoptosis in the tumor blood vessel endothelium, as supported by the specification at least at least at page 33, lines 5-12; and (ii) an agent that kills tumor cells or anti-angiogenic agent that inhibits metastasis of tumor cells, as supported by the specification at least from page 32, line 27 to page 33, line 3.

Dependent claim 45 separately recites a second anti-cancer agent as in claim 44 (b)(i), which increases aminophospholipid expression, or injures or induces apoptosis in the tumor blood vessel endothelium, supported by the specification at least at page 33, lines 5-12.

Claim 46 exemplifies agents in accordance with claim 45 as taxol, vincristine, vinblastine, neomycin, a combretastatin, a podophyllotoxin, TNF-α, angiostatin, endostatin, vasculostatin, an $\alpha_v\beta_3$ antagonist, a calcium ionophore or as a calcium-flux inducing agent (specification at page 33, lines 5-12), H_2O_2 or thrombin (Example XIV), an inflammatory cytokine (page 40, line 18; page 121, lines 16-23; Example XIV) or interleukin-4 (page 40, line 18; page 121, line 18).

Dependent claim 47 separately recites a second anti-cancer agent as in claim 44 (b)(ii), which kills tumor cells or is an anti-angiogenic agent that inhibits metastasis of tumor cells, as supported by the specification at least from page 32, line 27 to page 33, line 3.

Claim 48 exemplifies agents in accordance with claim 47 as an anti-tumor cell immunoconjugate, a chemotherapeutic agent or an anti-angiogenic agent, which are supported throughout the specification, with particular written description support at least from page 33, line 13 to page 35, line 21.

It will therefore be understood that no new matter is included within the amended or new claims.

V. Restriction and Species Issues

Although it is acknowledged that claims 1-30 and 34-43 are pending, the Action states that claims 2, 13, 15-18, 30 and 36-38 "are withdrawn from further consideration, as being drawn to nonelected species. Applicant timely traversed the restriction (election) requirement in Paper No. 14" (Fourth Action at page 2). These statements are in error.

The claims drawn to non-elected species cannot be withdrawn from "further" consideration, but remain pending and are rejoined upon allowance of a generic or other linking claim. 37 C.F.R. § 1.141(a). The continued withdrawal of many of the claims directed to the originally non-elected species is improper, and further, is inconsistent with the claims already examined on the merits. For example, claim 13 should be examined with claim 3, claims 30 and 38 should be examined with claim 1, and claim 37 should be examined with claims 1 and 34. In addition, the original species elections were made without traverse.

VI. Rejection of Claims 1, 3-12, 14, 19-22 and 39-43 Under 35 U.S.C. § 102(e)

Claims 1, 3-12, 14, 19-22 and 39-43 stand rejected under 35 U.S.C. § 102(e) as allegedly being anticipated by U.S. Patent No. 6,300,308 to Schroit ("Schroit"). Although Applicants respectfully traverse, the Action's concerns are overcome.

The following response should not be interpreted as an acquiescence that the effective filing of date Schroit is earlier than the effective filing date of the present application, nor as waiving any rights to establish a date of invention earlier than the effective filing date of Schroit.

Within examined claims 1, 3-12, 14, 19-29, 34, 35 and 39-43, each of claims 23-29, 34 and 35 are free from this ground of rejection. Without acquiescing with the present rejection in any way, Applicants presently introduce claims 44-48, which are based upon and extend claims 34 and 35. As detailed below, claims 1, 3-12, 14, 19-29, 34, 35 and 39-43, and new claims 44-48, are novel over Schroit.

Claim 1 recites a kit comprising a first anti-cancer agent in the form of a first antibody, or an antigen-binding fragment thereof, which binds to an aminophospholipid; and either a detectably-labeled antibody that also binds to an aminophospholipid or a second anti-cancer agent other than the first anti-aminophospholipid antibody or fragment thereof. Examination has focused on kits with second anti-cancer agents.

Schroit does not teach or suggest a kit comprising a first anti-cancer agent in the form of a first antibody, or an antigen-binding fragment thereof, which binds to an aminophospholipid, in combination with either a detectably-labeled antibody that also binds to an aminophospholipid or a second anti-cancer agent other than the first anti-aminophospholipid antibody or fragment thereof.

The rejection is largely based on the position that the first and second anti-cancer agents recited in present claim 1 can be exactly the same agent and, consequently, that the kits of claim 1 would be anticipated by a kit containing two aliquots of the same first anti-aminophospholipid antibody or fragment thereof. Such a position is in error.

Despite the plain meaning of the claim, which recites that the second anti-cancer agent is an anti-cancer agent other than the first anti-aminophospholipid antibody or fragment thereof, the Action takes the position that the claim "is not limited to two distinct antibodies directed to aminophospholipids" and that the second anti-cancer agent "encompasses any anticancer agent" (Third Action at page 3). According to the broadest reasonable interpretation of the claims, the second anti-cancer agent encompasses any second anti-cancer agent other than an anti-aminophospholipid antibody or fragment thereof. To determine otherwise would be inconsistent with the language of the claim itself and the controlling case law, which requires that the broadest reasonable interpretation of the claims must be consistent with the interpretation that those skilled in the art would reach. *In re Cortright,* 49 USPQ2d 1464, 1468 (Fed. Cir. 1999).

The Action's claim interpretation, which ignores the claim term "other than", attempts to read a limitation out of the claims, which is prohibited. Every element of a claim has meaning; the language of the claim as a whole must be considered and an interpretation should not be reached that renders a clause superfluous. *Genentech Inc. v. Chiron Corp.*, 42 USPQ2d 1608, 1612 (Fed. Cir. 1997). Claims should not be read so as to improperly broaden the scope of the claims 'reading out' the limitations in claim language. *Lockheed Martin Corp. vs. Space Systems/Loral Inc.* 58 USPQ2d 1671, 1678 (Fed. Cir. 2001).

There is no reasonable interpretation of claim 1 to support the Action's contention that this claim is not limited to two distinct anti-cancer agents. The § 102(e) rejection, essentially based on the position that the first and second anti-cancer agents recited in claim 1 can be the same, is therefore in error and should be withdrawn. Should the Office maintain its interpretation of the claims and the resultant § 102(e) rejection, Applicants respectfully request that the Office identify the particular statutory or judicial authority and scientific reasoning underlying the proposed claim interpretation.

Aside from the improper claim interpretation, which underlies most of the rejection, the Action's additional comments also fail to support the § 102 rejection. A rejection on the grounds of anticipation requires the disclosure, in a single reference, of every element of a claimed invention and requires that each and every facet of the claimed invention be identified in the applied reference. *Minnesota Mining & Mfg. v. Johnson & Johnson Orthopaedics, Inc.*, 24 USPQ2d 1321 (Fed. Cir. 1992). The Action's reference to different biological components mentioned in isolation in different sections of Schroit is insufficient to support an anticipation rejection of the present claims, which are drawn to "a kit", *i.e.*, a combination of components that are designed for use together:

"The kits of the present invention will also typically include a means for containing the vials, or such like, and other component, in close confinement for commercial sale, such as, *e.g.*, injection or blow-molded plastic containers into which the desired vials and other apparatus are placed and retained."

Specification at page 105, lines 15-18.

The lines and phrases in Schroit quoted at pages 3 and 4 of the Action do not teach or suggest kits with the elements of the present claims.

Schroit from column 7, line 67 to column 8, line 1 concerns one container with a PS composition and another container including "a matrix, solution, or other suitable <u>delivery device</u>" for applying "the composition" to the body. That is, one PS composition and one delivery device. The Action states that Schroit refers to PS composition<u>s</u>, and thus contends that Schroit discloses kits that can contain "a second anti-aminophospholipid antibody conjugate" (Fourth Action at page 3).

In response, the claims at issue are not directed to an "anti-aminophospholipid antibody conjugate", but to a naked or unconjugated anti-aminophospholipid antibody or fragment thereof in combination with a second, distinct anti-cancer agent. Even if Schroit refers to "PS composition<u>s</u>", including anti-PS antibody composition<u>s</u>, this would not anticipate the claimed invention. It is important to note that Schroit concerns <u>only</u> PS. Therefore, *even if* Schroit refers to "PS composition<u>s</u>", including anti-PS antibody composition<u>s</u>, such compositions *would have to be the same*. There is no teaching or suggestion in Schroit of a kit comprising a first anti-cancer agent in the form of an anti-aminophospholipid antibody, or fragment thereof, and a second anti-cancer agent <u>other than</u> the first anti-aminophospholipid antibody or fragment, as in the claimed invention.

The Action's further comments regarding claim 21, PS-polypeptide conjugates, separate moieties to be conjugated and diphtheria toxoid (Fourth Action at pages 3 and 4) have largely

been taken out of context of the Schroit document (see below), but in any event, these separate aspects of Schroit do not teach or suggest the kits of the claimed invention.

Schroit at claim 21 does not recite an "antibody-therapeutic construct" (Third Action at page 3). Claim 21 of Schroit concerns a method for generating a lipid-specific antibody response by administering a PS-polypeptide conjugate in which PS is conjugated to the carrier BSA, KLH, BGG, diphtheria toxin or β2-glycoprotein I. The administered composition is thus not an antibody-therapeutic agent construct. In any event, the claims at issue are not directed to an antibody-therapeutic agent construct, but to a naked or unconjugated anti-aminophospholipid antibody or fragment thereof and a second, distinct anti-cancer agent.

Schroit's reference to an antibody that can exist in "separate moieties to be conjugated by user of the kit" (Third Action at page 3) concerns immunodetection reagents alone, in particular, "antibody-label conjugates", which can be in fully conjugated form or as intermediates or separate moieties to be conjugated (Schroit at column 6, lines 50-51).

The discussion of diphtheria toxoid in Schroit is limited to its use as a carrier, *i.e.*, when conjugated to PS. There is no teaching regarding the use of diphtheria toxoid as any form of therapeutic agent alone.

Importantly, irrespective of the context of the PS-polypeptide conjugates, immunodetection moieties to be conjugated and diphtheria toxoid carriers in Schroit, the Action has still not identified any aspect of Schroit that teaches or suggests a kit comprising an anti-aminophospholipid antibody or fragment thereof in combination with a second, distinct anti-cancer agent.

For at least the foregoing reasons, claims 1, 3-12, 14, 19-22 and 39-43 are therefore novel over Schroit. Claims 13, 30 and 38, which have been improperly withdrawn from consideration, are also novel over Schroit.

As claims 34 and 35 are free from the § 102(e) rejection, each of claims 44-48, which are based upon claims 34 and 35, are also novel over Schroit. Each of claims 44-48, directed to the therapeutic kits of claim 34 in conjunction with defined properties of the first antibody, and particularly, with additional features of the second anti-cancer agent, is also novel over Schroit for the same and additional reasons.

Claim 44 is directed to a therapeutic kit in accordance with claim 34 in which the second anti-cancer agent is defined according to certain preferred features, particularly as an anti-cancer agent that (i) increases aminophospholipid expression, or injures or induces apoptosis in the tumor blood vessel endothelium; or that (ii) kills tumor cells or is an anti-angiogenic agent that inhibits metastasis of tumor cells. Claims 45 and 46 separately recite the two groups of second anti-cancer agents, and claims 47 and 48 provide particular examples of each. Claims 44-48 are therefore novel for the same reasons as claim 34, and further because Schroit does not teach or suggest anti-cancer agents that increase aminophospholipid expression, injure or induce apoptosis in tumor blood vessel endothelium, or that kill or inhibit the metastasis of tumor cells, let alone teach or suggest such anti-cancer agents as part of a kit in accordance with the present claims.

The § 102(e) rejection over Schroit is therefore overcome and should be withdrawn.

VII.   Rejection of Claims 1, 3-12, 14, 19-29, 34, 35 and 39-43 Under 35 U.S.C. § 103(a)

Next, the Action rejects claims 1, 3-12, 14, 19-29, 34, 35 and 39-43 under 35 U.S.C. § 103(a) as allegedly being legally obvious over the foregoing Schroit patent in view of U.S. Patent No. 5,632,991 to Gimbrone ("Gimbrone") and Umeda et al., J. Immunol., 143:2273-2279, 1989, ("Umeda"). Although Applicants respectfully traverse, the Action's concerns are addressed.

The Action states that claims 1, 3-12, 14, 19-29, 34, 35 and 39-43 "stand rejected" under § 103(a) over Schroit, Gimbrone and Umeda. In fact, this is a new ground of rejection as applied to claims 1, 3-12, 14, 19-22 and 39-43. As claims 3-12, 14, 19-22 and 39-42 were pending, non-amended claims, finality of the Third Action is premature and cannot be maintained (see **Section II**).

The Action again takes the position that "the instant second anticancer agent encompasses any anticancer agent" (Third Action at page 4). The claims clearly recite a first anti-cancer agent in the form of a first antibody, or an antigen-binding fragment thereof, which binds to an aminophospholipid and a second anti-cancer agent <u>other than</u> the first anti-aminophospholipid antibody or fragment thereof. Therefore, in the broadest reasonable interpretation of the claims, the second anti-cancer agent encompasses any second anti-cancer agent <u>other than</u> an anti-aminophospholipid antibody or fragment thereof.

Any other interpretation of the claims would be inconsistent with the plain language of the claim itself and the controlling case law. *In re Cortright, supra; Lockheed Martin Corp. vs. Space Systems/Loral Inc., supra.* Should the Office maintain its interpretation of the claims contrary to their plain meaning, Applicants respectfully request that the Office identify the particular authority underlying the proposed claim interpretation.

The § 103(a) rejection, like the § 102(e) rejection, is essentially based on the erroneous claim interpretation and the position that the first and second anti-cancer agents recited in the claims can be the same. As the interpretation of the claims set forth in the Action is clearly in error, the § 103(a) rejection is based on faulty reasoning and is *prima facie* improper and should be withdrawn. The rejection is further overcome for the following additional reasons.

The Action next contests Applicants' last response on the basis that one cannot show non-obviousness by attacking references individually where the rejections are based upon a

combination of references (Third Action at page 4). In fact, the scope and content of the prior art must be ascertained before the obviousness or nonobviousness of the claimed subject matter can be determined. *Graham v. John Deere Co.*, 148 USPQ 459, 467 (U.S.S.Ct. 1966). Moreover, although the Action refers to the combination of references <u>after</u> formulating the rejection, some suggestion to combine the disclosure of two or more references in an attempt to establish *prima facie* obviousness must be established <u>before</u> the P.T.O. may combine references. *In re Fine*, 5 USPQ2d 1596, 1598-99 (Fed. Cir. 1988). The Action's assessment of the references is anyway incorrect and does not actually support their combination.

After setting forth the rejection, the Action takes the position that the three cited references are viewed to be in the same field of endeavor and are considered combinable because "each reference is directed to specific receptor molecule on the surface of human vascular endothelial cells associated with vascularized tumor" (Third Action at page 5). This statement not only improperly characterizes the references, but is <u>derived from the present application and not from the cited art</u>, and therefore has no place in an obviousness enquiry. It is impermissible to use the claims as a frame and the prior-art references as a mosaic to piece together a facsimile of the claimed invention. *Uniroyal Inc. v. Rudkin-Wiley Corp.*, 5 USPQ2d 1434 (Fed. Cir. 1988).

Schroit concerns PS and reports that, as opposed to the situation in normal cells, PS may appear at the surface of tumor cells (Schroit throughout, *e.g.*, column 16, lines 27-33). Gimbrone concerns E-selectin expression on activated endothelium in certain diseases or infections, particularly in inflammation, and in connection with the metastatic spread of tumor cells (Gimbrone throughout, *e.g.*, Abstract, column 4, line 57 to column 5, line 7). Umeda concerns the direct immunization of PS-coated *Salmonella* into mouse spleen and stereo-specific aspects

of antigen recognition by monoclonal antibodies (Umeda throughout, *e.g.*, Abstract and page 2274).

None of Schroit, Gimbrone or Umeda teaches or suggests expression of PS, other aminophospholipids, E-selectin or any other specific receptor molecule on the surface of human vascular endothelial cells associated with a vascularized tumor. The statement in the Action at page 5 is therefore in error and the first ground advanced to support the combination of references is without merit. By referring to information from the present application, rather than from any of the cited references, this statement also evidences the Action's improper use of hindsight in formulating the rejection. To imbue one of ordinary skill in the art with knowledge of the invention in suit, where no prior art reference or references of record convey or suggest that knowledge, is to fall victim to the insidious effect of a hindsight syndrome wherein that which only the inventor taught is used against its teacher. *W.L. Gore Assoc., Inc. v. Garlock, Inc.*, 220 USPQ 303, 312-313 (Fed. Cir. 1983).

The Action at page 5 further takes the position that Schroit, Gimbrone and Umeda are combinable because they are "used for the same purpose". This statement is also in error and thus fails to support the proposed combination or the resultant § 103 rejection. The purpose of Schroit is immunization with PS-polypeptide conjugates to generate PS-specific antibodies, which may bind to tumor cells; the purpose of Gimbrone is treat diseases and infections associated with E-selection expression on activated endothelium, particularly inflammation; and the purpose of Umeda is direct intrasplenic immunization with PS-coated *Salmonella* and stereo-specific analysis of PS recognition by antibodies. These three references are therefore not directed to the same purpose and the references have been improperly combined.

Importantly, even if combined, Schroit, Gimbrone and Umeda do not teach or suggest the presently claimed invention, and particularly do not teach or suggest a kit comprising a first

23

antibody, or an antigen-binding fragment thereof, which binds to an aminophospholipid and a second anti-cancer agent other than such a first anti-aminophospholipid antibody or fragment.

In attempting to show a suggestion towards the claimed kits in Schroit, the Action refers to Schroit at column 7, line 67 to column 8, line 1 and states, "Schroit sets forth that multiple PS antibody compositions can be used in Schroit's kit. Therefore, Schroit's suggests [*sic*] kits that can contain containers with a second anti-aminophospholipid antibody conjugate" (Third Action at page 4). As set forth above, the claims at issue are not directed to first or second "anti-aminophospholipid antibody conjugates", but to a naked or unconjugated anti-aminophospholipid antibody or fragment thereof in combination with a second, distinct anti-cancer agent.

Even if Schroit refers to "multiple PS antibody compositions", including multiple anti-PS antibody compositions, there is no suggestion of a kit in accordance with the claimed invention. It is important to note that Schroit concerns only PS. Therefore, *even if* Schroit refers to multiple anti-PS antibody compositions, any such compositions *have to be the same*. Schroit therefore cannot suggest a kit comprising a first anti-cancer agent in the form of an anti-aminophospholipid antibody, or fragment thereof, and a second anti-cancer agent other than the first anti-aminophospholipid antibody or fragment, as in the claimed invention.

The Action next takes the position that "the instant therapeutic constructs within the kits do not exclude such constructs [PS-polypeptide conjugates] as taught by Schroit" (Third Action bridging pages 4 and 5). Should the Action be referring to the first anti-cancer agent, the anti-aminophospholipid antibody or fragment of the claims clearly excludes PS-polypeptide conjugates as in Schroit. Should the Action be implying that a PS-polypeptide conjugate as in Schroit could be a second anti-cancer agent within the scope of the claims, this is far removed from rendering the invention of claims 1, 3-12, 14, 19-29, 34, 35 and 39-43 legally obvious.

It is well established under the law that an invention must be viewed in its entirety in formulating an obviousness rejection. The test for obviousness is not whether individual differences between the claims and the prior art are obvious but, rather, whether the claimed invention <u>as a whole</u> is obvious. *In re Buehler*, 185 USPQ 781 (CCPA 1975). "The entirety of a claimed invention, including the combination viewed as a whole, the elements thereof, and the properties and purposes of the invention must be considered." *In re Wright*, 6 USPQ 2d 1959 (Fed. Cir. 1988).

The Action has still not identified any aspect of Schroit that teaches or suggests a kit comprising a first antibody or fragment thereof that binds to an aminophospholipid in combination with a second, distinct anti-cancer agent. The line of argument that a PS-polypeptide conjugate of Schroit would be a second anti-cancer agent within the scope of the claims pertains to only one element of the claimed kit, and lacks any suggestion of the claimed invention *as a whole*.

Schroit therefore fails to teach or suggest the claimed invention. Indeed, the acknowledged novelty of several claims, such as claims 34 and 35, and the lack of a § 103 rejection of any claim based upon Schroit *alone* is an admission that Schroit does *not suggest* the presently claimed invention. The Action therefore relies on Gimbrone and Umeda to cure the deficiencies of Schroit (Third Action at page 5). However, Gimbrone and Umeda have been improperly combined with Schroit, and even if properly combined, Schroit, Gimbrone and Umeda together fail to teach or suggest the kits of the present invention.

Neither Gimbrone nor Umeda teach or suggest the claimed kits or second anti-cancer agents, or in any way cure the deficiencies of Schroit. Gimbrone is silent as to antibodies that bind to aminophospholipids (Second Action at page 8). Umeda concerns intrasplenic immunization methods to generate anti-phospholipid antibodies, but only for use in investigating

molecular mechanisms of PS interactions (Umeda at page 2273, column 2, second paragraph). The Office agrees that "Umeda does not teach the use of his antibodies in kits for diagnostic or therapeutic purposes" (Second Action at page 9). Thus, the secondary references each fail to teach or suggest the first anti-cancer agent of the claimed kits.

The Action cites Gimbrone and Umeda to "supplement the teachings of Schroit to further provide for a second anticancer agent or therapeutic agent" (Third Action at page 5). It appears that Gimbrone, as well as Umeda, in fact lacks any teaching or suggestion of a kit with first and second therapeutic agents of any type. Gimbrone and Umeda particularly fail to teach or suggest a kit with a first and second anti-cancer agent. Gimbrone was earlier cited as concerning second E-selectin-based therapeutic agents at columns 12, 14 and 15 (Third Action at page 8), but these sections of Gimbrone are limited to an anti-E-selectin antibody, fragment or conjugate when used alone. The Office admitted that Umeda does not teach the use of a therapeutic agent (Second Action at page 9). The secondary references thus fail to teach or suggest kits with two distinct anti-cancer agents, as required by the present claims.

In failing to teach or suggest both the first and second anti-cancer agents required by the present claims, Gimbrone and Umeda are incapable of curing the admitted deficiencies of Schroit. For at least the foregoing reasons, claims 1, 3-12, 14, 19-29, 34, 35 and 39-43 are therefore novel and non-obvious over Schroit, Gimbrone and Umeda, even if properly combined. Certain of the pending claims are also patentable over the cited references for various additional reasons[1].

---

[1]Claims drawn to kits in which the first anti-cancer agent is an antibody or fragment that binds to phosphatidylethanolamine, although withdrawn from consideration, are further patentable, as the cited references do not teach or suggest a therapeutic antibody that binds to phosphatidylethanolamine, let alone such an antibody as part of a kit in combination with a second, distinct anti-cancer agent. Schroit teaches away from these aspects of the invention by the objective to produce highly-specific anti-PS antibodies (Schroit at column 2, line 36) and by the description of the resultant antibodies as being able to recognize PS but not DPOE (dioleoyl phosphatidylethanolamine) in a bilayer membrane (Schroit at column 25, lines 24-26).

Claims 39-42 recite kits in which the anti-aminophospholipid antibodies or fragments are functionally defined as binding to an aminophospholipid on the luminal surface of tumor vascular endothelial cells and as exerting particular anti-vascular effects. These claims are further patentable as the cited references do not teach or suggest the expression of aminophospholipids on the luminal surface of tumor blood vessels or anti-vascular effects of anti-aminophospholipid antibodies, let alone teach or suggest a kit comprising such antibodies in combination with a second anti-cancer agent.

The surprising discovery that aminophospholipids are accessible, stable markers of tumor vasculature (specification at page 4, lines 29-30), as recited in claims 39-42, also underlies many surprising features of claims 1, 19-29, 34, 35 and 44-48. This finding in itself was particularly surprising, as the tumor vascular endothelial cells are normal cells, taught in the prior art to preserve PS in the inner leaflet (see Schroit at column 16, lines 28-31). Relatively stable PS expression at the cell surface of normal cells was not known prior to the present invention.

The finding that PS was a marker of the normal cells of the tumor vasculature provided a means for effective therapy, overcoming the problems associated with tumor cell targeting, such as tumor cell resistance, antigen escape and effective penetration into the tumor. The inventors also unexpectedly discovered that naked antibodies against aminophospholipids are capable of specifically localizing to tumor vasculature and inducing tumor blood vessel destruction and tumor necrosis *in vivo* in the absence of conjugation to effector molecules. The invention thus provides single component therapeutics directed against tumor vasculature for use in the safe and effective treatment of solid tumors (specification at page 5, lines 5-10).

Importantly, the translocation of aminophospholipids to the surface of tumor vascular endothelial cells was further discovered to occur, at least in a significant part, independently of cell damage and apoptopic or other cell-death mechanisms (specification at page 5, lines 12-14).

This discovery of sufficiently stable expression on morphologically intact tumor-associated vascular endothelial cells, which is again in contrast to the prior art (as evidenced by Schroit), was an important step in the development of effective therapies (specification at page 5, lines 15-18).

In addition to providing effective anti-vascular tumor therapy with naked antibodies, as opposed to the difficulties associated with tumor cell targeting, the present discovery of sufficiently stable aminophospholipid expression on normal tumor vasculature endothelial cells gave rise to the combined anti-cancer therapeutics described in the present application and recited in the pending claims. In particular, a first antibody or fragment that binds to an aminophospholipid on the luminal surface of the vascular endothelial cells of the blood vessels of a vascularized tumor and another agent selected for "simultaneously or sequentially administering to the animal a therapeutically effective amount of at least a second anti-cancer agent" (specification from page 32, line 11 to page 33, line 12; see also **Section J** of the specification). Therefore, the present invention, unlike the cited prior art, provides for the intelligent selection of first and second anti-cancer agents in a kit for use together.

These aspects of the invention are highlighted in claims 44-48, which are directed to therapeutic kits in which the second anti-cancer agent is selected for combined use according to the guidance provided in the specification. A second anti-cancer agent administered at a biologically effective time *prior* to the anti-aminophospholipid antibody is taught to (i) increase aminophospholipid expression, or injure or induce apoptosis in the tumor blood vessel endothelium (specification at page 33, lines 5-12); whereas a second anti-cancer agent administered at a biologically effective time *subsequent* to the anti-aminophospholipid antibody is taught to (ii) kill tumor cells or to be an anti-angiogenic agent that inhibits metastasis of tumor cells (specification from page 32, line 27 to page 33, line 3).

Schroit, Gimbrone and Umeda, even if properly combined, do not teach or suggest anti-cancer agents that increase aminophospholipid expression, injure or induce apoptosis in tumor blood vessel endothelium, or that kill or inhibit the metastasis of tumor cells, let alone teach or suggest such agents as the second anti-cancer agent in a kit comprising a first anti-cancer agent in the form of an unconjugated antibody or fragment thereof that binds to an aminophospholipid on the luminal surface of the vascular endothelial cells of the blood vessels of a vascularized tumor. The present application, in contrast, teaches the rationale for selecting such agents in combination along with detailed teaching concerning second anti-cancer agents within each category.

The manuscript enclosed as **Exhibit A** provides actual data to support the reasoning in the application, showing that various factors and tumor-associated conditions known to be present in the tumor microenvironment are able to cause PS translocation in cultured endothelial cells. Hypoxia/reoxygenation, acidity, thrombin, and inflammatory cytokines, such as IL-1α, IL-1β, TNFα and IFN, are all shown to induce PS exposure without causing cytotoxicity. Hydrogen peroxide is also shown to be a strong inducer of PS, and inflammatory cytokines and hypoxia-reoxygenation are shown to have greater than additive effects, supporting the inventors' surprising findings that factors in tumors interact to give amplified effects on PS-exposure on the normal tumor vascular endothelial cells *in vivo*. All such information, and its effective use to provide the kits of the claimed invention, exists in the present application but not in the cited art.

The rejection under 35 U.S.C. § 103(a) is thus overcome and should be withdrawn.

VIII. Application Serial No. 09/351,149

The present application has the same filing date and priority date as co-owned Application Serial No. 09/351,149 ("the '149 application"; Attorney Docket No. 3999.002383)

co-pending before the Examiner. In third and fourth Official Actions in the '149 application, the Office entered a provisional rejection of all examined claims under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over one or more claims in the present application. In regard to the claims in the '149 application and the present claims, the Office states:

> "Although the conflicting claims are not identical, they are not patentably distinct from each other because they are both directed to kits comprising antibodies directed to aminophospholipids and a second anti cancer agent"

Fourth Action in the '149 application at page 5; emphasis added.

The Office further maintains that the scope of the claims in the '149 application "overlap" with the scope of the claims pending in the present application (Fourth Action in the '149 application at pages 5 and 6).

A provisional double patenting between two co-pending applications, by its very nature, requires the Office to consider the claims in the two applications to be legally obvious, each over the other. MPEP 804 at page 800-19. This is evident in the provisional double patenting rejection entered in the '149 application, which refers to the conflicting claims not being patentably distinct "from each other" and states that the claims "overlap".

However, a provisional double patenting rejection over the '149 application has not been entered in the present application. In the absence of such a rejection in this application, the provisional double patenting rejection in the '149 application is *prima facie* improper and must be withdrawn as legally and procedurally inconsistent. MPEP 804. To maintain the rejection in the '149 application, the Office must also enter a provisional double patenting rejection in the present application. Any such rejection would have to be made as part of a Non-Final Office Action, being a new ground of rejection not necessitated by Applicants' amendment or untimely submission of references.

IX. Conclusion

This is a complete response to the referenced Official Action. In conclusion, Applicants submit that, in light of the foregoing remarks, the present case is in condition for allowance and such favorable action is respectfully requested. Should Examiner Sharareh have any questions or comments, or identify any informalities, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,

```
||||||||||||||||||||||||
23720
```
PATENT TRADEMARK OFFICE

Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicant

WILLIAMS, MORGAN & AMERSON, P.C.
10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: April 22, 2003

Phosphatidylserine is a marker of tumor vasculature and a potential target for anti-cancer drugs[1]

Sophia Ran[2], Neal Rote[3] and Philip E. Thorpe[2]

Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
2201 Inwood, Dallas, Texas 75390-8594 and the Department of Pharmacology
UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9111

Running title: PS is a marker of tumor vessels
Key words: Phosphatidylserine, tumor endothelium, apoptosis, tumor targeting

[2] To whom correspondence should be addressed at 2201 Inwood Road, NC7.304, Dallas, Texas 75390-8594. Phone: (214) 648-1628; Fax: (214) 648-1613; E-mail: sophia.ran@utsouthwestern.edu

[3] Dept. Microbiology and Immunology, Wright State University, Dayton, OH 45435

Abbreviations used in this paper are: TF, tissue factor; VCAM-1, vascular cell adhesion molecule 1; IL-1a, interleukin-1 alpha; DPBS, Dulbecco's phosphate buffered saline; HRP; horseradish peroxidase; AP, alkaline phosphatase; SMC, smooth muscle cells; SCID, severe combined immunodeficient; PS, Phosphatidylserine; CL, cardiolipin; ROS, reactive oxygen species.

ABSTRACT

Phosphatidylserine (PS) is a phospholipid that almost exclusively resides on the inner

leaflet of the plasma membrane under normal conditions. PS translocation to the external

side of the membrane (PS exposure) is associated with apoptosis, necrosis, cell injury, cell

activation and malignant transformation. We previously reported that endothelial cells in

tumor vessels of Hodgkin's lymphoma implanted in mice express PS on their external

surface. Endothelial cells in normal tissues did not express detectable amounts of PS. In

the present study, we analyzed five additional tumor models for the exposure of PS on

tumor vasculature and investigated a potential mechanism underlying this phenomenon.

Anti-PS antibody specifically localized to tumor blood vessels in all tumors (HT29 human

colon adenocarcinoma, NCI-H358 human lung carcinoma, B16 mouse melanoma, 3LL

mouse lung carcinoma and Colo 26 mouse colon carcinoma). No localization was detected

on normal endothelium. An isotype-matched control antibody directed against a different

negatively charged lipid, cardiolipin, did not localize to either tumor or normal

endothelium. Frozen tumor sections were examined for the presence of apoptotic cells,

using a double labeling technique that detected a pan-endothelial cell marker and the

apoptosis markers, active caspase 3 and fragmented DNA (Tunel assay). Neither apoptosis

marker was present in tumor endothelium, indicating that PS-positive tumor vessels are

seldom apoptotic. Externalization of PS also did not correlate with the maturation status of

the vessels, as an abnormal pericytic network was equally evident around PS-positive and

PS-negative tumor vessels. Various factors and tumor-associated conditions known to be

present in the tumor microenvironment were examined for their ability to cause PS

translocation in cultured endothelial cells. Hypoxia/reoxygenation, acidity, thrombin, and

inflammatory cytokines all induced PS exposure without causing cytotoxicity. Hydrogen

peroxide was also a strong inducer. Possibly, conditions inside tumors generate reactive

oxygen species that induce PS exposure. Combined treatment with inflammatory cytokines and hypoxia/reoxygenation had greater than additive effects, suggesting that factors may interact to give amplified effects on PS-exposure on tumor endothelium *in vivo*. Since PS is absent from the outer surface of normal endothelium, its exposure on tumor vessels could potentially be utilized for tumor vessel targeting and imaging.

INTRODUCTION

Phosphatidylserine (PS) is a phospholipid that almost exclusively resides in the inner leaflet of the plasma membrane under normal conditions (1; 2). PS asymmetry is maintained by an ATP-dependent aminophospholipid translocase that is responsible for inward movement of aminophospholipids (3-5). Loss of PS asymmetry results from the outward movement of PS in the plasma membrane and is caused either by inhibition of the translocase (6; 7) or activation of scramblase, a Ca^{2+} dependent enzyme that transports lipids bidirectionally (8; 9). Loss of PS asymmetry is observed under different pathological and physiological conditions, including programmed cell death (10; 11), cell aging (12), intercellular fusion of myoblasts (13) and trophoblasts (14), cell migration (15; 16), activation of platelets (17-19) and cell degranulation (20). Endothelial cells externalize PS in response to thrombin (21) hyperlipidemia (22), viral infection (23), non-lytic concentrations of complement proteins C5b-9 (24) or exposure to calcium ionophore A23187 and PMA (25). Spontaneous PS exposure has been also observed in malignant cells in the absence of exogenous activators or cell injury (26-28).

Several major consequences follow membrane PS exposure. Phagocytic macrophages recognize, attach and eliminate PS-positive senescent and apoptotic cells (29; 30). PS also mediates attachment of T lymphocytes to thrombin-activated endothelial cells (21). The complement system is activated by PS and contributes to the lysis of PS-positive cells (31). Finally, PS exposure contributes to a procoagulant shift on the endothelium (1; 11) by providing a negatively charged lipid surface for assembly and activation of coagulation complexes (32; 33).

A mouse monoclonal IgM, 3SB, directed against PS has been raised and characterized by

Rote and colleagues (17). The antibody binds to PS but not to phosphatidylcholine,

phosphatidylethanolamine or cardiolipin (CL). 3SB binds to PS-coated ELISA plates in

the presence or absence of serum, indicating that PS binding does not require cofactors.

3SB binds to cells having exposed PS (17). It is possible that it recognizes hexagonally

packed PS, which has been reported to be antigenic (34).

We previously discovered that 3SB localized to tumor blood vessels in mice bearing

human Hodgkin's disease tumors. This finding indicated that endothelial cells in

Hodgkin's tumors, in contrast to those in normal tissues, expressed PS on the external

surface of their plasma membrane. In the present study, we determined whether vascular

PS exposure is observed in other types of tumors, and investigated the causes of PS

translocation. PS exposure on tumor vasculature was present in all of six different tumors

growing in mice. PS exposure was not due to apoptosis of tumor endothelium, or to

irregularities in their coating with perivascular cells. Studies with cultured endothelial cells

showed that hypoxia/reoxygenation, acidity, thrombin, and inflammatory cytokines caused

PS exposure without causing cytotoxicity. Hydrogen peroxide did likewise.

Hypoxia/reoxygenation, acidity, thrombin and inflammatory cytokines may therefore act

individually or collectively in tumors to generate peroxide ions and other reactive oxygen

species that induce PS exposure on tumor endothelium.

PS on tumor vessels may provide a target molecule for the vascular targeting or imaging of

vessels in solid tumors. Annexin V, an endogenous PS-binding ligand, has been used

successfully to image PS-expressing activated platelets in thrombi (35), apoptotic cells in

rejecting cardiac allografts, cyclophosphamide-treated lymphomas and anti-Fas antibody-

treated livers in rodents (10). Anti-PS antibodies may be directly cytotoxic to tumor vasculature, or mediate the binding of cytotoxic or coagulation factor to tumor vessels complement, host cells. Also, anti-PS antibodies, annexin V and other ligands that bind specifically to PS on tumor endothelial cells might be used to deliver a cytotoxic drug, radionuclide or coagulant to tumor vessels. Vascular targeting agents directed against markers on mature blood-transporting vessels in tumors have caused destruction of tumor vasculature and major tumor regressions in other systems (36-38). The present studies suggest the use of PS-directed antibodies and immunoconjugates for the vascular targeting or imaging of tumor vessels in man.

MATERIALS AND METHODS

Materials. $Na^{125}I$ was obtained from Amersham (Arlington Heights, IL). Dulbecco's modified Eagle's tissue culture medium and Dulbecco PBS containing Ca^{2+} and Mg^{2+} were obtained from Gibco (Grand Usland, NY). Fetal calf serum was obtained from Hyclone (Logan, Utah). O-phenylenediamine, hydrogen peroxide and thrombin were from Sigma (St. Louis, MO). Flat bottom plates with 24 wells were obtained from Falcon (Becton Dickinson and Co., Lincoln Park, NJ). Recombinant murine interleukin-1 alpha, beta and tumor necrosis factor alpha (TNF α) were purchased from R&D Systems (Minneapolis, MN). Interferon of Universal Type I (hybrid protein that substitutes for all types of interferons) was purchased from PBL Biomedical Laboratories (New Brunswick, NJ). Recombinant hepatocyte growth factor (HGF or scatter factor) and actinomycin D were from Calbiochem. Recombinant VEGF, PDGF-BB, $TGF\beta_1$, interleukin–6 (IL-6),

interleukin-8 (IL-8), interleukin-10 (IL-10) and FGF-1 were purchased from PeproTech (Rocky Hill, NJ).

Antibodies

Mouse monoclonal anti-PS and anti-CL IgM antibodies were raised as described (17). Both antibodies have been extensively characterized with regard to the specificity of their binding to PS and CL respectively (17). MECA 32, a pan mouse endothelial cell antibody, was kindly provided by Dr. E. Butcher (Stanford University, CA) and served as a positive control for immunohistochemical studies. Details of this antibody have been published (39). Rabbit anti-rat immunoglobulin, rat-anti mouse immunoglobulin and goat-anti mouse immunoglobulin secondary antibodies conjugated to horseradish peroxidase (HRP) or alkaline phosphatase (AP) were purchased either from Daco (Carpinteria, CA) or from Jackson Immunoresearch Labs (West Grove, PA).

Cells

L540Cy Hodgkin lymphoma cells, derived from a patient with end-stage disease, were provided by Prof. V. Diehl (Köln, Germany). HT29 human colon adenocarcinoma and NCI-H358 human non-small cell lung carcinoma were provided by Dr. Adi Gazdar (Southwestern Medical Center, Dallas, TX). B16 mouse melanoma and 3LL mouse lung carcinoma were obtained from American Type Cell Collection (Rockville, MD). Colo 26 mouse colorectal carcinoma was a gift from Dr. Ian Hart (ICRF, London, UK). The mouse brain endothelioma, bEnd.3, was provided by Prof. Werner Risau (Max Plank Institution, Munich, Germany).

METHODS

Tissue Culture

bEnd.3 cells, adult bovine aortic endothelial (ABAE) cells and all tumor cells except

L540Cy lymphoma cells were maintained in DMEM supplemented with 10% fetal calf

serum, 2 mM L-glutamine, 2 units/ml penicillin G and 2 ug/ml streptomycin. L540Cy cells

were maintained in RPMI 1640 containing the same additives. Cells were sub-cultured

once a week. Trypsinization of bEnd.3 cells was performed using 0.125% trypsin in PBS

containing 0.2% EDTA. For *in vitro* studies, endothelial cells were seeded at a density of

$1x10^4$ cells/ml in 1 ml of culture medium in 24 well plates and incubated 48-96 hours

before being used in the assays. Medium was refreshed 24 hours before each experiment.

Growth of tumor cells *in vivo*

For localization studies, $2x10^7$ L540 human Hodgkin's lymphoma cells or $1x10^7$ cells of

other tumor types were injected subcutaneously into the right flank of SCID mice (Charles

River, Wilmington, MA). Tumors were allowed to reach a volume of 0.4-0.7 cm^3. A

minimum of three animals per tumor group was used. Experiments were performed at least

three times.

Detection of PS exposure on tumor endothelium *in vivo*

Detection of exposed PS *in vivo* was performed essentially as previously described (37).

Briefly, anti-PS or anti-CL mouse IgM antibodies (30 ug/mouse) were injected

intravenously in 200 ul of saline. Thirty minutes later mice were sacrificed and their blood

circulation was exsanguinated and perfused with heparinized saline as previously described

(40). All major organs and tumor were harvested and snap-frozen for preparation of

cryosections. Mouse IgM was detected using goat anti mouse IgM (μ specific) - HRP conjugate followed by development with carbazole (41). The number of positive vessels per high power field was determined at magnification of x 40. At least 10 random fields per section were examined and the average percentage of positive vessels was calculated.

Detection of apoptosis in tumors *in situ*

The blood circulation of mice was perfused with heparinized saline as previously described (40). Tumors were dissected out and snap-frozen for cryosectioning. Cytosolic and nuclear alterations characteristic for apoptotic cells were detected immunohistochemically by using two markers: active caspase-3 (42) and fragmented DNA (43). Active caspase-3 was detected by a rabbit anti-caspase-3 specific antibody (R&D, Minneapolis, MN) followed by incubation with anti-rabbit IgG conjugated to alkaline phosphatase (AP, Pierce, Rockford, IL). Other tumor sections were analyzed by Tunel assay (ApopTag kit, Oncor, MD) using anti-digoxigenin–alkaline phosphatase conjugate as a detecting reagent. To determine whether tumor endothelial cells express apoptotic markers, sections were sequentially labeled with MECA 32 (anti-endothelial marker) and anti rat-HRP secondary antibody, followed by either anti-caspase-3 antibody or Tunel assay and AP-conjugated secondary reagents. Vessels were visualized by their brown color, using Stable DAB (Research Genetics, Huntsville, AL) as a substrate. Apoptotic cells were identified by their pink-purple color (kit from Research Genetics) created by the phosphatase activity of secondary reagents detecting markers of apoptosis. The pink-purple stain was clearly distinguishable from the brown stain, if both markers coincided. These conditions of double labeling permitted the sequential detection of both enzymes.

Detection of pericytes on tumor frozen sections

To characterize interactions between PS-positive vessels and pericytes, tumor sections were double-labeled by goat anti mouse IgM-HRP (to identify anti-PS localized antibody) followed by anti α-smooth muscle cell actin (α-SMC) antibody (Daco, Carpinteria, CA), a marker of pericytes and vascular smooth muscle cells (SMC)(44; 45). The peroxidase activity was detected by Stable DAB and resulted in brown color. The pericytic marker was detected by anti mouse IgG-AP conjugate and resulted in a pink-purple color. Substrates for both enzymes were from Research Genetics. In other experiments, the endothelium was first detected by MECA 32 IgG and visualized by DAB, followed by anti α-SMC antibody and AP-mediated detection of pericytes/SMC.

Iodination of annexin V

Recombinant human annexin V was purified from E. coli transformed with ET12a-PAP1 plasmid (a gift from Dr. J. Tait, University of Washington, Seattle). The purity of the protein and the binding to PS were confirmed on SDS-PAGE and on PS-coated plastic, respectively. Rabbit polyclonal, affinity-purified anti-annexin V antibody was used to detect annexin V bound to PS. Annexin V was radiolabeled with ^{125}I using Chloramine T as described by Bocci (46). The specific activity was approximately $1x10^6$ cpm per ug of protein, as measured by a Bradford assay (47).

Effect of growth factors, cytokines, inflammatory mediators, hydrogen peroxide, hypoxia and acidic pH on translocation of PS in cultured endothelial cells

Endothelial cells were treated with cytokines or growth factors at the concentrations listed in Table 3. All reagents were diluted in medium containing 10% serum and incubated with the cells at 37°C for 24 hours. To study the effect of hypoxia, cells were seeded on 24 well

plates and were incubated in a humidified normoxic atmosphere (21% O_2, 5% CO_2) for 48

hours before being transferred to a humidified hypoxic atmosphere (1% O_2, 5% CO_2, 94%

N_2) in a sealed chamber (Billups Rothenberg inc, Del Mar, Ca). Cells were incubated in a

hypoxic chamber for 24 hours at 37°C and the cells were compared to a parallel culture

maintained under normoxic conditions. In some experiments, IL-1α (10 ng/ml) and TNFα

(20 ng/ml) were added to medium prior to transfer to a hypoxic chamber.

To examine the effect of an acidic microenvironment, cells were exposed to the growth

medium lacking bicarbonate, which was adjusted to different pHs (ranged between 7.3 to

6.2) with the required amount of HCl. Cells were incubated at 37°C in the absence of CO_2.

Preservation of the medium pH in the presence of cell monolayer during 24 hours period

was confirmed in each experiment. Under these experimental conditions all tested reagents

were non-toxic to either bovine or mouse endothelial cells and had no effect on cell

morphology or viability of the attached monolayer.

Detection of exposed PS on cultured endothelial cells by ^{125}I-labeled annexin V

After treatment with the reagents described above, treated and control cells were incubated

with 7.1 pmoles of ^{125}I-labeled annexin V (200 ul/well) in the binding buffer. After 2 hours

incubation at room temperature, cells were washed extensively and dissolved in 0.5 M of

NaOH. The entire volume of 0.5 ml was transferred to plastic tubes and counted in a

gamma counter. Non-specific binding was determined in the presence of 5 mM EDTA and

was subtracted from experimental values. The results were expressed as net pmoles of cell-

bound annexin V, normalized per 1×10^6 cells. Maximal binding of annexin V was

determined on cells simultaneously treated with actinomycin D and TNFα (50 ng/ml of

each component). As has been previously reported, combination of the above agents

causes apoptosis and PS exposure in the 100 percent of the treated endothelial cells (48).

Basal binding of ^{125}I-annexin V to untreated cells was determined in the presence of medium with 10% serum. The amount of ^{125}I-annexin V that bound to the untreated cultures was subtracted from that in the treated cultures. The specific increase in the amount of externalized PS was calculated according to the following formula: (net experimental binding / net maximal binding) X 100. Each experiment was performed in duplicate and was performed at least three times.

Detection of exposed PS on endothelial cells *in vitro* by biotinylated annexin V

Endothelial monolayers were washed with DPBS containing Ca^{2+} and Mg^{2+} and fixed with 0.25% of glutaraldehyde diluted in the same buffer. Excess aldehyde groups was quenched by incubation with 50 mM of Na_4Cl for 5 minutes. Cells were washed with DPBS (containing Ca^{2+}, Mg^{2+} and 0.2% gelatin) and incubated with 1 ug/ml of biotinylated annexin V (Pharmingen, San Diego, CA). After 2 hours of incubation, cells were washed with 0.2% gelatin buffer incubated with streptavidin-HRP (1:500 dilution). Detection of PS *in situ* was confirmed by staining with anti-PS IgM. Anti-CL IgM and streptavidin were used as negative controls in these assays. All steps were performed at room temperature. PS-positive cells were detected by addition of carbazole substrate, resulting in insoluble red-brownish precipitate. The number of positive cells per high power field was determined and expressed as a percent of the total number of cells. Six random fields were scored per well and the average was calculated.

RESULTS

PS is a marker of tumor vasculature.

PS exposure on vascular endothelium *in vivo* was detected by a specific anti-PS mouse IgM, (3SB) as previously described (37). A class and species matched antibody, D11 (17),

directed against a different negatively charged phospholipid, CL, served as a negative control. CL exclusively resides in the membrane of mitochondria (49). This anti-CL monoclonal antibody recognizes CL, not PS or other lipids (17).

All six tumors included in this study contained PS-positive vessels (Fig.1 and Table 1). The percentage of PS-positive vessels ranged from 40% in B16 tumors to 10% in Colo 26 tumors. Anti-PS IgM was present on the luminal surface of capillaries and venules in all regions of the tumors. PS-positive vessels appeared to be particularly prevalent in and around regions of necrosis. Positive vessels usually did not show morphological abnormalities that were apparent by light microscopy. Occasional vessels located in necrotic areas showed morphological signs of deterioration. Detection of PS by 3SB was specific since no staining of tumor endothelium was observed with the anti-CL antibody. Anti-PS antibody (but not anti-CL antibody) also localized to necrotic and apoptotic tumor cells. No vascular localization of anti-PS or anti-CL antibodies was observed in normal organs other than the kidneys (Table 1). In the kidneys, tubules were stained in both anti-PS and anti-CL recipients, presumably because of secretion of IgM through this organ. These findings demonstrate that PS is present on the luminal surface of vascular endothelial in various tumors but not in normal tissues.

PS-positive tumor vessels are not apoptotic

A double labeling technique was used to identify apoptotic endothelial cells in tumor sections. Apoptotic cells were identified with two independent markers: an active form of caspase-3, which identifies cytosolic changes in dying cells (42), and fragmented DNA, which identifies cells having nuclear alterations (43). Active caspase-3 was detected by a specific antibody. Fragmented DNA was visualized by Tunel assay (43). Cells positive for apoptotic markers were stained pink by AP-labeled secondary reagents. Endothelial cells in blood vessels were stained brown by HRP-labeled by a pan-endothelial antibody, MECA

32. Both colors were clearly visible on the same cells, if endothelial and apoptotic markers coincided.

Endothelial cells in five out of six types of tumors (HT29, H358, B16, Colo 26, L540) did not display either of the apoptosis markers (Fig. 2, Table 2). The sixth type of tumor, 3LL, displayed a few apoptotic endothelial cells that were located in necrotic areas. In contrast, apoptotic malignant cells were common in all types of tumors. The percentage of apoptotic tumor cells ranged from 1-2% in L540 tumors to 12.6-19.6% in 3LL tumors. There was broad correspondence between the number and location of tumor cells that stained positively for active caspase 3 and for fragmented DNA. However, cells displaying active caspase 3 were about 1.5 times as abundant as those with fragmented DNA, probably because active caspase 3 is an earlier and less specific marker of apoptosis than is fragmented DNA.

Lack of correlation between PS-positive tumor vessels and abnormal distribution of pericytes

We explored whether abnormalities in the perivascular cell coating of tumor vessels might account for their PS exposure by determining whether there was a correlation between the integrity of the coating by pericytes and the positivity for externalized PS. Frozen tumor sections from mice that had been injected with anti-PS antibody or anti-CL antibody were double labeled for the presence of the vascular endothelial cell marker, MECA 32, and a pericytic cell/SMC marker, αSMC-actin. Endothelial cells were stained brown while pericytic cells were stained pink. PS-positive tumor vessels were identified in sequential sections by staining for localized anti-PS IgM (brown) followed by identification of pericytes (pink). In contrast to the continuous pericytic layer surrounding vascular

endothelial cells in normal tissues, vessels in all tumors had a discontinuous and

disorganized network of pericytic cells (Fig. 3). Vessels in B16 melanomas and Colo 26

carcinomas almost completely lacked pericytes. HT29 and H358 carcinomas contained

pericytes/SMC that were often totally separated from endothelial cells. The L540

lymphoma was the only tumor of those examined that had a major percentage (about 40%)

of vessels in which pericytic cells were properly attached.

There was no correlation between irregularities in pericytic cells and exposure of PS on

tumor vessels (Fig. 3). PS-positive and PS-negative tumor endothelium had equal

proportions of coated vessels, uncoated vessels and vessels with partly detached pericytic

layers. Abnormalities in pericyte coating, therefore, do not appear to be the cause of PS

translocation on tumor endothelium.

Inducers of PS translocation by endothelial cells *in vitro*

Endothelial cells *in vitro* were treated with non-toxic concentrations of various factors and

conditions that are present in the microenvironment of many tumors (50-54). The factors

included: angiogenic factors (VEGF, HGF and bFGF) tumor and host cell–derived

inflammatory and pro-angiogenic cytokines (1L-1α, IL-1β, TNFα, IL-6, IL-8, IL-10 and

interferons), thrombin, hypoxia/reoxygenation , oxygen-reactive species and low pH.

These conditions are all known to perturb endothelial cells and could be considered as

potential cause of PS translocation. Activation, perturbation and injury of endothelium by

these factors and conditions are associated with a rise of intracellular Ca^{2+} concentration.

The rise in intracellular Ca^{2+} might activate scramblase (9) and simultaneously inhibit

aminophospholipid translocase (6), leading to accumulation of PS on the external side of

the membrane.

Mouse bEnd.3 or bovine ABAE cells were treated for 24 hours with different concentrations of potential inducers of PS translocation. PS externalization was quantified by measuring ^{125}I-annexin V binding. The amount of annexin V binding was compared with that of cells in which apoptosis of 100% of cells had been induced by combined treatment with actinomycin D and TNF-α. Actinomycin D and TNF-α induced the binding of 6.2 pmoles of annexin V per 10^6 cells (3.8 x 10^6 molecules of annexin V per cell) on both cell types, in good agreement with literature reports (55). This value was taken as the maximal amount of externalized PS.

Untreated cells were largely devoid of externalized PS, as judged by annexin V or anti-PS antibody binding (Table 3, and Fig. 4A). The basal binding in the presence of growth medium alone was 0.44 and 0.68 pmoles of ^{125}I-annexin V for ABAE and bEnd.3 cells, respectively. This corresponds to 7.06% and 10.9% of the maximal binding for ABAE and bEnd.3 cells, respectively, which correlated well with the finding that approximately 10% of cells bound biotinylated annexin V under the same conditions. VEGF, HGF, FGF, TGFβ_1, PDGF, IL-6, IL-8 and IL-10 did not increase binding of ^{125}I-annexin V above the basal level for untreated cells. Inflammatory mediators (IL-1α, IL-1β, TNFα and interferon) caused a small but reproducible increase in PS translocation that ranged from 6 to 8% of the maximal level for ABAE cells and from 7 to 14% for bEnd3 cells (Table 3). Hypoxia/reoxygenation, thrombin or acidic external conditions (pH 6.8-6.6) induced a moderately high externalization of PS that ranged from 8 to 20% of the maximal level for ABAE cells and from 17 to 22% of the maximal level for bend.3 cells. The largest increase in PS translocation was observed after treatment with 100 to 200 uM of hydrogen peroxide. This treatment caused nearly complete (95%) externalization of PS in both cell types as judged by ^{125}I-annexin V binding (Table 3). More than 70% of ABAE and bEnd.3

cells bound biotinylated annexin V, as judged immunohistochemically (Fig. 4B). PS-expressing endothelial cells generated by treatment with hypoxia/reoxygenation, thrombin, acidity, TNFα, IL-1 or H_2O_2 remained attached to the matrix during time period of the assay (24 hours), retained cell-cell contact (Fig. 4B) and retained their ability to exclude trypan blue dye. Normal PS orientation was restored 24 to 48 hours later in the majority of the cells. These results indicate that mild oxidative stress, created by direct application of H_2O_2 or indirectly by hypoxia/reoxygenation, acidity, thrombin, or inflammatory cytokines, triggers a transient translocation of PS on viable endothelial cells.

Combined Effects of Inflammatory Cytokines and Hypoxia/Reoxygenation on PS-Exposure by Endothelial Cells *In Vitro*

Enhanced PS exposure was observed when ABAE cells were subjected to hypoxia/reoxygenation in the presence of IL-1α or TNFα. In the absence of the cytokines, hypoxia/reoxygenation increased PS-exposure by ABAE cells to 15% of the maximum level for cells treated with apoptotic concentrations of actinomycin D and TNFα. In the presence of subtoxic concentrations of IL-1α or TNFα, hypoxia/reoxygenation increased PS-exposure to 26% and 33% respectively of the maximum (Fig. 5). Cytokines in the absence of hypoxia/reoxygenation increased PS-exposure by less than 7% indicating that the combination of cytokines and hypoxia/reoxygenation had greater than additive effects on PS-exposure. Thus, in tumors, the PS-inducing effect of hypoxia/reoxygenation may be amplified by inflammatory cytokines and possibly by such other stimuli as acidity and thrombin.

DISCUSSION

The major finding to emerge from this study is that vascular endothelial cells in tumors externalize PS to their luminal surface where it can be bound by a specific anti-PS antibody *in vivo*. PS is absent from the external surface of vascular endothelial cells in normal tissues, suggesting that PS-recognizing antibodies, annexin V and other ligands might be used for delivering cytotoxic drugs, coagulants or radionuclides for the selective destruction or imaging of vessels in solid tumors.

PS-positive tumor endothelium appears to be viable. It does not display markers of apoptosis, it is morphologically intact and metabolically active, as indicated by its expression of VCAM-1, E-selectin and other rapidly turned-over proteins. Although often regarded as an indicator of apoptosis, PS exposure has been observed in several types of viable cells, including malignant cells (27; 28; 55), activated platelets (17), and embryonic trophoblasts at various stages of migration, matrix invasion and fusion (14). Recent studies suggest that constitutive PS exposure on malignant cells may occur because expression of truncated (less active) aminophospholipid translocase, as detected by epitope-specific antibodies against the putative PS translocase, ATPaseII[4]. Lack of correlation between PS exposure and commitment to cell death has been also shown on pre-apoptotic B lymphoma cells that restored PS asymmetry and grew normally after removal of pro-apoptotic stimulus (56). In normal viable cells, PS exposure is probably triggered by surface events, such as ligand-receptor interactions, that induce Ca^{2+} fluxes into the cells (57). Ca^{2+} fluxes activate scramblase (9) and simultaneously inhibit aminophospholipid translocase (6).

To shed light on the mechanism of PS exposure on tumor endothelial cells, a series of experiments was performed in which endothelial cells *in vitro* were treated with various factors and conditions known to be present in the tumor microenvironment. The objective was to identify factors that induce PS exposure on endothelial cells without causing cytotoxicity in order to mimic the situation in tumors *in vivo*. Hypoxia followed by reoxygenation, acidity, and thrombin increased PS exposure on viable endothelial cells to between 10 and 22% of the level seen when all cells are apoptotic. Inflammatory cytokines (TNFα and IL-1α) also caused a weak but definite induction of PS exposure. The possibility that these conditions are in fact the major inducing stimuli in tumors *in vivo* is suggested by the following: i) PS positive endothelium is prevalent in and around regions of necrosis where hypoxia, acidity, thrombosed blood vessels, and infiltrating host leukocytes are commonly observed; ii) the finding that hypoxia/reoxygenation amplifies the weak PS-exposing activity of TNFα and IL-1 on endothelial cells *in vitro* (Fig. 5) correlates with the situation *in vivo* in tumors where hypoxia and cytokine-secreting tumor and host cells co-exist; iii) hypoxia/reoxygenation and thrombin have been reported to generate reactive oxygen species (e.g. peroxides) in endothelial cells through activation of NADPH oxidase-like membrane enzyme (58; 59). Hydrogen peroxide was the most powerful inducer of PS exposure on cultured endothelial cells found in the present study, providing indirect support for the involvement of reactive oxygen species. Based on these findings we propose the following cascade of events leading to PS exposure on tumor vessels, which indirectly contributes to tumor-associated thrombosis (Fig. 6). Hypoxia/reoxygenation in combination with inflammatory cytokines, thrombin and acidity are responsible in part for generation of ROS by endothelial and tumor cells. ROS are also produced by infiltrating host cells (macrophages, neutrophils and granulocytes) that are

attracted by necrosis and tumor-derived cytokines. Tumor endothelial cells respond to

rising ROS concentration by transferring PS to the external side of the membrane. The

externalized PS provides the negative phospholipid surface upon which coagulation factors

concentrate and assemble. This confers the procoagulant status to the tumor endothelium

that has long been recognized. PS also provides an attachment site for circulating

macrophages (29), T lymphocytes (21) and polymorphonuclear cells that assist in

leukocyte infiltration into tumors. Adherence of activated macrophages,

polymorphonuclear cells and platelets to PS on tumor endothelium may lead to further

secretion of reactive oxygen species and further amplification of PS exposure.

Anti-PS antibodies might be used for cancer therapy in several ways. Unconjugated

antibodies might directly suppress tumor endothelial cell growth or survival by interfering

with critical PS-dependent surface functions. This hypothesis is supported by the studies on

viable B cells demonstrating that PS neutralization inhibits signaling from the cell surface

via B cell receptor (57). Anti-PS antibodies might also mediate toxicity by binding

complement and cytotoxic cells, by inducing apoptosis or by promoting pro-thrombotic

status of tumor vascular endothelium. In certain autoimmune disorders, anti-

aminophospholipid antibodies cause normal tissue damage by analogous mechanisms (60-

62). Also, anti-PS antibodies or ligands might be linked to various effector molecules (e.g.

cytotoxic drugs, radionuclides, coagulants) to create vascular targeting agents that destroy

or occlude blood vessels in solid tumors. Such agents have been shown to be highly

effective, and sometimes curative, in mice with large solid tumors (36; 38).

PS on tumor vessels is attractive as a target for several reasons: it is abundant (minimum

of 3×10^6 molecules per cell); it is on the luminal surface of tumor endothelium, which is

directly accessible for binding by vascular targeting agents in the blood; it is present on a high percentage of tumor endothelial cells in diverse solid tumors, and it is absent from endothelium in all normal tissues examined to date. Unconjugated antibodies, vascular targeting agents and imaging agents directed against PS on tumor vasculature potentially could have utility for cancer treatment in man.

Acknowledgment

REFERENCES

1. Williamson, P. and Schlegel, R.A., Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Molec.Mem.Biol. 11, 199-216, 1994.

2. Zwaal, R.F. and Schroit, A.J., Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89(4), 1121-1132, 1997.

3. Devaux, P.F., Protein involvement in transmembrane lipid asymmetry. Annu Rev Biophys Biomol Struct 21, 417-439, 1992.

4. Mouro, I., Halleck, M.S., Schlegel, R.A., Mattei, M., Williamson, P., Zachowski, A., Devaux, P., Cartron, J.P., and Colin, Y., Cloning, expression, and chromosomal mapping of a human ATPase II gene, member of the third subfamily of P-type ATPases and orthologous to the presumed bovine and murine aminophospholipid translocase. Biochem.Biophys.Res Commun. 257(2), 333-339, 1999.

5. Seigneuret, M. and Devaux, P.F., ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proc Natl.Acad.Sci.USA 81(12), 3751-3755, 1984.

6. Comfurius, P., Senden, J.M., Tilly, R.H., Schroit, A.J., Bevers, E.M., and Zwaal, R.F., Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim.Biophys.Acta 1026(2), 153-160, 1990.

7. Bitbol, M., Fellmann, P., Zachowski, A., and Devaux, P.F., Ion regulation of phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human erythrocytes. Biochim.Biophys.Acta 904(2), 268-282, 1987.

8. Zhou, Q., Zhao, J., Stout, J.G., Luhm, R.A., Wiedmer, T., and Sims, P.J., Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J.Biol.Chem. 272, 18240-18244, 1997.

9. Zhao, J., Zhou, Q., Wiedmer, T., and Sims, P.J., Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface. J.Biol.Chem. 273, 6603-6606, 1998.

10. Blankenberg, F.G., Katsikis, P.D., Tait, J.F., Davis, R.E., Naumovski, L., Ohtsuki, K., Kopiwada, S., Abrams, M.J., Darkes, M., Robbins, R.C., Maecker, H.T., and Strauss, H.W., In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl.Acad.Sci.USA 95(11), 6349-6354, 1998.

11. Bombeli, T., Karsan, A., Tait, J.F., and Harlan, J.M., Apoptotic vascular endothelial cells become procoagulant. Blood 89, 2429-2442, 1997.

12. Herrmann, A. and Devaux, P.F., Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes. Biochim.Biophys.Acta 1027(1), 41-46, 1990.

13. Sessions, A. and Horwitz, A.F., Myoblast aminophospholipid asymmetry differs from that of fibroblasts. FEBS Lett. 134(1), 75-78, 1981.

14. Adler, R., Ng, A.-K., and Rote, N.S., Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol.Reprod. 53(4), 905-910, 1995.

15. Vogt, E., Ng, A.-K., and Rote, N.S., A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. Am J Obstet Gynecol 174(2), 700-707, 1996.

16. Balch, C. and Dedman, J.R., Annexins II and V inhibit cell migration. Exp Cell Res 237(2), 259-263, 1997.

17. Rote, N.S., Ng, A.-K., Dostal-Johnson, D.A., Nicholson, S.L., and Siekman, R., Immunologic detection of phosphatidylserine externalization during thrombin-induced platelet activation. Clin.Immunol.Immunopathol. 66, 193-200, 1993.

18. Zwaal, R.F., Bevers, E.M., Comfurius, P., Rosing, J., Tilly, R.H., and Verhallen, P.F., Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells; mechanisms and physiological significance. Mol Cell Biochem 91(1-2), 23-31, 1989.

19. Sims, P.J., Faioni, E.M., Wiedmer, T., and Shattil, S.J., Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol.Chem 263(34), 18205-18212, 1988.

20. Demo, S.D., Masuda, E., Rossi, A.B., Throndset, B.T., Gerard, A.L., Chan, E.H., Armstrong, R.J., Fox, B.P., Lorens, J.B., Payan, D.G., Scheller, R.H., and Fisher, J.M., Quantitative measurement of mast cell degranulation using a novel flow cytomeric annexin-V binding assay. Cytometry 36(4), 340-348, 1999.

21. Qu, J., Conroy, L.A., Walker, J.H., Wooding, F.B., and Lucy, J.A., Phosphatidylserine-mediated adhesion of T-cells to endothelial cells. Biochem J 317(pt. 2), 343-346, 1996.

22. Lupu, F., Moldovan, N., Ryan, J., Stern, D., and Simionescu, N., Intrinsic procoagulant surface induced by hypercholestrolaemia on rabbit aortic endothelium. Blood Coagul Fibrinolysis 4(5), 743-752, 1993.

23. van Geelen, A.G., Slobbe-van Drunen, M.E., Muller, A.D., Bruggeman, C.A., and Van Dam-Mieras, M.C., Membrane related effects in endothelial cells induced by human cytomegalovirus. Arch Virol 140(9), 1601-1612, 1995.

24. Christiansen, V.J., Sims, P.J., and Hamilton, K.K., Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arterioscler Thromb Vasc Biol 17(1), 164-171, 1997.

25. Julien, M., Millot, C., Tocanne, J.F., and Tournier, J.F., 12-O-tetradecanoylphorbol-13-acetate uinhibits aminophospholipid translocase activity and modifies the lateral motions of fluorescent phospholipid analogs in the plasma membrane of bovine aortic endothelial cells. Exp Cell Res 234(1), 125-131, 1997.

26. Cichorek, M., Kozlowska, K., Witkowski, J.M., and Zarzeczna, M., Flow cytometric estimation of the plasma membrane diversity of transplantable melanomas, using annexin V. Folia Histochem.Cytobiol. 38(1), 41-43, 2000.

27. Utsugi, T., Schroit, A.J., Connor, J., Bucana, C.D., and Fidler, I.J., Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51(11), 3062-3066, 1991.

28. Sugimura, M., Donato, R., Kakkar, V.V., and Scully, M.F., Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. Blood Coagul Fibrinolysis 5(3), 365-373, 1994.

29. McEvoy, L., Williamson, P., and Schlegel, R.A., Membrane phospholipid asymmetry as a determinant of erythocyte recognition by macrophages. Proc Natl.Acad.Sci.USA 83(10), 3311-3315, 1986.

30. Tait, J.F. and Smith, C., Phosphatidylserine receptors: role of CD36 in binding of anionic phospholipid vesicles to monocytic cells. J Biol.Chem 274(5), 3048-3054, 1999.

31. Test, S.T. and Mitsuyoshi, J., Activation of the alternative pathway of complement by calcium-loaded erythrocytes resulting from loss of membrane phospholipid asymmetry. J Lab Clin Med 130(2), 169-182, 1997.

32. Bevers, E.M., Rosing, J., and Zwaal, R.F., Development of procoagulant binding sites on the platelet surface. Adv.Exp.Med.Biol. 192, 359-371, 1985.

33. Dachary-Prigent, J., Toti, F., Satta, N., Pasquet, J.M., Uzan, A., and Freyssinet, J.M., Physiopathological significance of catalytic phospholipids in the generation of thrombin. Seminars.In Thrombosis.&.Hemostasis. 22, 157-164, 1996.

34. Aguilar, L., Ortega-Pierres, G., Campos, B., Fonesca, R., Ibanez, M., Wong, C., Farfan, N., Naciff, J.M., Kaetzel, M.A., and Dedman, J.R., Phospholipid membranes form specific nonbilayer molecular arrangements that are antigenic. J Biol.Chem 274(36), 25193-25196, 1999.

35. Tait, J.F., Cerqueira, M.D., Dewhurst, T.A., Fujikawa, K., Ritchie, J.L., and Stratton, J.R., Evaluation of annexin V as a platelet-directed thrombus targeting agent. Thromb.Res. 75, 491-501, 1994.

36. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T.S., and Thorpe, P.E., Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547-550, 1997.

37. Ran, S., Gao, B., Duffy, S., Watkins, L., Rote, N.S., and Thorpe, P.E., Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58(20), 4646-4653, 1998.

38. Nilsson, F., Kosmehl, H., Zardi, L., and Neri, D., Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61(2), 711-716, 2001.

39. Leppink, D.M., Bishop, D.K., Sedmak, D.D., Henry, M.L., Ferguson, R.M., Streeter, P.R., Butcher, E.C., and Orosz, C.G., Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation 48(5), 874-877, 1989.

40. Burrows, F.J., Watanabe, Y., and Thorpe, P.E., A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res. 52, 5954-5962, 1992.

41. Fries, J.W.U., Williams, A.J., Atkins, R.C., Newman, W., Lipscomb, M.F., and Collins, T., Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am.J.Pathol. 143, 725-737, 1993.

42. Krajewska, M., Wang, H.G., Krajewski, S., Zapata, J.M., and Shabaik, A., Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 57(8), 1605-1613, 1997.

43. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A., Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119(3), 493-501, 1992.

44. Shepro, D. and Morel, N.M., Pericyte physiology. FASEB J 7(11), 1031-1038, 1993.

45. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., and Keshet, E., Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103(2), 159-165, 1999.

46. Bocci, V., Efficient labeling of serum proteins with 131I using chloramine T. Int.J.Appl.Radiat.Isot. 15, 449-456, 1964.

47. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal.Biochem. 72, 248-254, 1976.

48. Lucas, R., Garcia, I., Donati, Y.R., Hribar, M., Mandriota, S.J., Giroud, C., Buurman, W.A., Fransen, L., Suter, P.M., Nunez, G., Pepper, M.S., and Grau, G.E., Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells. Eur J Immunol 28(11), 3577-3586, 1998.

49. Daum, G., Lipids of mitochondria. Biochim.Biophys.Acta 822(1), 1-42, 1985.

50. Lichtenbeld, H.H., Van Dam-Mieras, M.C., and Hillen, H.F., Tumour angiogenesis: pathophysiology and clinical significance. Neth J Med 49(1), 42-51, 1996.

51. Harris, A.L., Zhang, H., Moghaddam, A., Fox, S., Scott, P., Pattison, A., Gatter, K., Stratford, I., and Bicknell, R., Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Res.Treat 38(1), 97-108, 1996.

52. Raleigh, J.A., Dewhirst, M.W., and Thrall, D.E., Measuring Tumor Hypoxia. Semin Radiat Oncol 6(1), 37-45, 1996.

53. Toyokuni, S., Okamoto, K., Yodoi, J., and Hiai, H., Persistent oxidative stress in cancer. FEBS Lett 358(1), 1-3, 1995.

54. Kraus, M. and Wolf, B., Implications of acidic tumor microenvironment for neoplastic growth and cancer treatment: a computer analysis. Tumour.Biology. 17(3), 133-154, 1996.

55. Rao, L.V.M., Tait, J.F., and Hoang, A.D., Binding of annexin V to a human ovarian carcinoma cell lines (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity. Thromb.Res. 67, 517-531, 1992.

56. Hammill, A.K., Uhr, J.W., and Scheuermann, R.H., Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res 251(1), 16-21, 1999.

57. Dillon, S.R., Mancini, M., Rosen, A., and Schlissel, M.S., Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation. J Immunol 164(3), 1322-1332, 2000.

58. Holland, J.A., Meyer, J.W., Chang, M.M., O'Donnel, R.W., Johnson, D.K., and Ziegler, L.M., Thombin stimulated reactive oxygen species production in cultured human endothelial cells. Endothelium 6(2), 113-121, 1998.

59. Zulueta, J.J., Yu, F.S., Hertig, I.A., Thannickal, V.J., and Hassoun, P.M., Release of hydrogen peroxide in response to hypoxia-reoxygenation: role of an NAD(P)H oxidase-like enzyme in endothelial cell plasma membrane. Am J Respir Cell Mol Biol 12(1), 41-49, 1995.

60. Vogt, E., Ng, A.-K., and Rote, N.S., Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am J Obstet Gynecol 177(4), 964-972, 1997.

61. Ferro, D., Pittoni, V., Quintarelli, C., Basili, S., Saliola, M., Caroselli, C., Valesini, G., and Violi, F., Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 95(6), 1425-1432, 1997.

62. Nakamura, N., Shidara, Y., Kawaguchi, N., Azuma, C., Mitsuda, N., Onishi, S., Yamaji, K., and Wada, Y., Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Commun 205(2), 1488-1493, 1994.

Table 1 Specific localization of anti-PS and anti-CL antibodies to tumor vessels mice

Tissue	Anti-PS[a]	Anti-cardiolipin
L540 tumor	++[b]	-
H358 tumor	++	-
HT29 tumor	+	-
B16 tumor	+++	-
3LL tumor	++	-
Colo 26 tumor	++	-
Adrenal	-	-
Brain	-	-
Heart	-	-
Kidney	-[c]	-[c]
Intestine	-	-
Liver	-	-
Lung	-	-
Pancreas	-	-
Spleen	-	-
Testis	-	-

[a]   Localization of anti-PS or anti-CL antibody in tumor bearing mice was determined by injecting the antibody, perfusing the blood circulation of the mice with saline and detecting the antibody on sections of the tissues by using an anti-mouse IgM - peroxidase conjugate.

[b]   Intensity of staining was compared to pan-endothelial marker MECA 32; - indicates no staining; + weak (fewer than 5% positive vessels) ; ++ moderate (5 to 20 %); +++ (20 to 40 %) strong.

[c]   Non-antigen specific tubular staining was visible in both anti-PS and anti-CL recipients.

Table 2 **Expression of apoptotic markers in tumors**

Tumor type	Active caspase-3		Tunel assay	
	Tumor cells (% of total)[a]	Tumor vessels	Tumor cells (% of total)	Tumor vessels
3LL	19.8	<1.0[b]	12.6	0
HT29	13.7	0	7.8	0
H358	5.8	0	4.3	0
Colo 26	5.3	0	4.1	0
B16	4.2	0	3.5	0
L540	2.3	0	1.6	0

[a] The percentage of tumor cells or tumor blood vessels that were positive for either caspase-3 or Tunel was determined in ten high power fields per section. The fields were randomly selected along two perpendicular directions from the edges through the center of the tumor. The average of the percentage of positive cells or vessels in tumor from 3 mice is presented.

[b] Occasional vessels (1 of >100) in the necrotic area of 3LL tumor displayed both markers of apoptosis.

Table 3 Effect of cytokines, growth factors and stress conditions on exposure of PS on endothelial cells *in vitro*.

Treatment	Concentration[a]	^{125}I-Annexin V (% of Max binding)[b]	
		ABAE cells	bEnd.3 cells
Medium with 10% serum	N/A[c]	0	0
Actinomycin D + TNF α	50 ng/ml each	100	100
VEGF	20 ng/ml	0	0
βFGF	20 ng/ml	0	0
Scatter factor	40 ng/ml	0	0
TGF β₁	20 ng/ml	0	0
PDGF-BB	20 ng/ml	0	0
IL-10	20 ng/ml	0	0
IL-8	20 ng/ml	0	0
IL-6	20 ng/ml	0	0
IL-1α	10 ng/ml	6.4	7.5
IL-1β	10 ng/ml	5.8	5.5
Interferon	40 ng/ml	8.6	2.8
TNFα	20 ng/ml	7.4	13.7
Thrombin	50 nM	8.8	17.4
Hypoxia	1% O₂	15.0	22.5
pH 6.6[d]	N/A	20.2	18.9
Hydrogen peroxide	100 uM[e]	95.5	98.4

[a] Concentrations of cytokines, growth factors and thrombin were selected from literature values to have maximal stimulatory effect on cultured endothelial cells. These concentrations did not cause toxicity over the period of the test (24 hours) as judged by morphological appearance, a lack of detachment, and a lack of uptake of trypan blue.

[b] Binding of ^{125}I-annexin V was performed as described under Methods. Basal binding was determined in the presence of growth medium alone. Maximal PS exposure was determined after induction of apoptosis by the combined treatment with actinomycin D and TNF α. Untreated ABAE and bEnd.3 cells bound 0.44 and 0.68 pmoles of ^{125}I-Annexin V, respectively. Maximal binding was 6.2 pmoles of ^{125}I-annexin V for both cell types (equivalent to 3.8×10^6 molecules per cell) The percentage of increase of annexin V binding was calculated according to the following formula: (net experimental binding / net maximal binding) X 100. Average of duplicates from three separate experiments is presented. SE was less than 5%.

[c] Not applicable.

[d] Cells were exposed to the growth medium lacking bicarbonate that had been adjusted to pH 6.6 with 1N HCl. Cells were incubated at 37°C in the absence of CO₂.

[e] The maximal concentration of H₂O₂ that did not cause cytotoxicity under chosen conditions.

Figure Legends:

Fig. 1. Localization of anti-PS antibody to vascular endothelial cells in L540 human Hodgkin's lymphoma, 3LL murine lung carcinoma and B16 murine melanoma tumors in mice. Tumor-bearing SCID mice were injected intravenously with 20 ug of anti-PS or anti-CL mouse IgM. The blood circulation was perfused with saline one hour later. Mice were sacrificed one hour later and tumor and organs were harvested and snap-frozen. Mouse IgM was detected on frozen sections using goat anti-mouse IgM-peroxidase conjugate. Anti-PS antibody specifically localized to blood vessels (indicated by arrows) in all tumors. No localization was observed in mice injected with control anti-CL IgM.

Fig. 2. Lack of apoptotic vascular endothelial cells in 3LL and L540 tumors. Frozen sections of 3LL and L540 tumors were double labeled with a pan-endothelial cell antibody, MECA 32 to visualize blood vessels, and with anti-apoptotic markers detecting either active caspase-3 or fragmented DNA (Tunel assay). MECA 32 staining of vessels is indicated by the brown color (arrows). Expression of apoptotic markers is indicated by the pink color (arrowheads). Both apoptotic markers are present in some tumor cells but are absent from tumor endothelium.

Fig 3. Pericyte-endothelial cell interactions in PS-positive and PS-negative vessels in 3LL tumors. Mice bearing 3LL tumors were injected with 20 ug of anti-PS IgM. PS-positive vessels (*upper panel*) were detected as described above. PS-negative vessels (defined as MECA 32 positive, anti-PS-negative) were identified on serial sections of the same tumor (*lower panel*). Vessels were labeled brown with the pan-endothelial cell marker. Pericytes were identified with anti-αSMC actin antibody and were stained pink (arrowheads). Representative fields of PS-positive, pericyte-negative (*upper left*), PS-positive, pericyte-positive (*upper right*), PS-negative, pericyte-negative (*lower left*) and PS-negative, pericyte-positive (*lower right*) vessels are shown. Note the detachment of the pericytic layer from tumor endothelium and the uneven distribution of pericytes along tumor vessels (*upper and lower right*).

Fig. 4. Externalized PS on bEnd.3 mouse endothelial cells treated with 100 uM of hydrogen peroxide. A) untreated bEnd.3 cells; B) bEnd.3 cells after treatment with 100 uM of hydrogen peroxide. PS is absent from the surface of untreated cells but becomes externalized after treating the cells with H_2O_2. PS-positive cells remain attached to the substratum, retain cell-cell contact and other morphological signs of viability.

Fig. 5. Synergistic effect of hypoxia and inflammatory cytokines on PS exposure. bEnd.3 cells were treated for 24 hours with IL-1 α and TNF α under normoxic and hypoxic conditions. PS externalization was determined on viable endothelial monolayer by measuring binding of ^{125}I-annexin V. The increase in PS exposure was calculated as explained under "Materials and Methods".

Fig. 6. Hypothesis for induction of PS exposure on tumor vessels and its contribution to the procoagulant shift of the tumor endothelium.